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Summary
PRP is widely used to treat tendon and other tis-
sue injuries in orthopaedics and sports medicine;
however, the efficacy of PRP treatment on injured
tendons is highly controversial.  In this commen-
tary, I reason that there are many PRP- and pa-
tient-related factors that influence the outcomes
of PRP treatment on injured tendons. Therefore,
more basic science studies are needed to under-
stand the mechanism of PRP on injured tendons.
Finally, I suggest that better understanding of the
PRP action mechanism will lead to better use of
PRP for the effective treatment of tendon injuries
in clinics. 
KEY WORDS: tendon injuries, tendinopathy, PRP, or-
thopaedics, sports medicine.
Recent increases in the popularity of sports and the
use of computers has created a rise in tendon injuries
in both athletic and occupational settings. Tendon in-
juries, both acute and chronic (or tendinopathy), low-
er the quality of life of affected individuals and in-
crease the costs of health care. Because injured ten-
dons undergo a slow and incomplete healing process
and often form scar tissue after healing, they are sus-
ceptible to re-injury1. Thus, restoring the normal stru -
cture and function to injured tendons remains one of
the greatest challenges in orthopaedics and sports
medicine. 
In recent years, physicians in the orthopaedics and
sports medicine field have adopted platelet-rich-plas-
ma (PRP) to treat injured tendons and other tissues2.
PRP is the plasma fraction of the blood; it contains
concentrated platelets and, in many cases, white
blood cells (WBCs). PRP is autologous and therefore
considered to be inherently safe; it provides a natural
conductive scaffold, and is a reservoir of many
growth factors (e.g. PDGF, TGF-β, VEGF, and HGF),
which can enhance healing of injured tissues includ-
ing tendons3,4. However, no study has thus far
demonstrated the exclusive role of PRP growth fac-
tors in enhancing tissue healing, and the role of other
molecules should also be considered5. 
PRP has been shown to effectively treat acute and
chronic tendon injuries6-9; however, little or no effect
was also reported by others when PRP was used to
treat similar conditions10-12. The current controversy
over PRP’s efficacy may be best addressed by basic
science studies performed on cellular and animal
models under well-controlled conditions. These mod-
els may include RNA silencing in vitro and gene
knock-out or knock-down in mice in vivo to address
specific functions of individual molecules contained in
PRP. For example, a novel transgenic strategy has
been recently developed to induce gene knock-down
in platelets, which will allow characterization of genes
involved in platelet production and the function of
platelets in mice13.
In two of our recent studies, we investigated the ef-
fect of PRP on tendon stem/progenitor cells (TSCs)
using a cell culture model14 and also determined the
anti-inflammatory effects of PRP on tendon inflamma-
tion using both culture and animal models15. In the
first study we aimed to test whether PRP treatment
can promote tendon healing14. For this, we prepared
PRP using methods that minimized the amounts of
leukocytes and named it as the ‘PRP-releasate’. Our
results showed that treating TSCs with PRP-releas-
ate induced TSC differentiation into active tenocytes,
which proliferated quickly and produced abundant
collagen, indicating the potential of PRP to enhance
the repair of injured tendons. Additionally, PRP did
not induce non-tenocyte differentiation into chondro-
cytes, adipocytes, or osteocytes16, suggesting that
PRP treatment does not increase the risk of non-
tendinous tissue formation in treated tendons. 
In the second study15, we demonstrated that PRP’s
anti-inflammatory function is mediated via HGF con-
tained in PRP by suppressing the levels of prosta -
glandin biosynthetic pathway components (COX-1,
COX-2, and mPGES-1 expression) and PGE2 produc-
tion. These results were corroborated by our animal
model studies where PRP injections (which may con-
tain small amounts of leukocytes due to difficulty in
removing all these cells from a small volume) re-
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duced COX-1 and COX-2 protein expression and low-
ered PGE2 levels in the wounded Achilles tendons of
mice. These results have clinical implications; high
levels of PGE2 are known to cause pain17-19, de-
crease cell proliferation and collagen production20,
cause aberrant differentiation of TSCs into non-teno-
cytes21, and induce degenerative changes in rabbit
tendons22. Therefore, PRP’s ability to reduce PGE2
production is expected to benefit the healing of in-
jured tendons. Additionally, growth factors contained
in PRP can stimulate tendon healing and the fibrin gel
in PRP can serve as a natural scaffold to attract cells,
thus resulting in enhanced tendon healing. 
Many conflicting results have been reported on the
efficacy of PRP treatment, which are due in part, to
the various factors that influence the outcome of
treatments in clinical settings. The most important
among them are PRP- and patient-associated fac-
tors. The PRP-related factors include: 1) type of
preparation, which varies significantly (some PRP
preparations contain WBCs, which release inflamma-
tory agents, such as IL-1β and TNF-α and hence may
cause catabolic effects on treated tissues); 2) platelet
concentration, which determines the amount of
growth factors present in PRP preparations; higher
concentration of platelets in PRP may not be neces-
sarily optimal at least for cell proliferation23; 3) use of
activated or non-activated PRP; non-activated PRP
may promote tissue healing more efficiently than acti-
vated PRP24; 4) method of PRP activation (the use of
calcium or thrombin may yield differential results); 5)
mode of application (whether injection or implantation
of PRP gel); and 6) frequency of PRP applications
during treatment. 
The patient-associated factors include: 1) age (PRP
is more effective in young patients, who have more
and better-quality stem cells); 2) type of tendon injury
(acute or chronic); 3) type of tissue injured (tendons
or other soft tissues); 4) patient activity level; 5) treat-
ment history; and 6) post-recovery plans (with or
without rehabilitation)25. Whether patients are in reha-
bilitation or resume daily activities after PRP treat-
ment could also be beneficial or detrimental. This is
because moderate mechanical loading is known to
suppress cellular inflammation26 and induce anabolic
changes in tendon cells, but excessive mechanical
loading worsens cellular inflammation by increasing
PGE2 production21 and inducing aberrant differentia-
tion of TSCs into non-tenocytes, which may lead to
degenerative tendinopathy16. 
In current clinical settings, PRP is prepared by cen-
trifugation and a pre-determined dose is used for all
types of tissue injuries. This “one-size-fits-all” ap-
proach is sub-optimal and, not surprisingly, skews the
outcom e of PRP treatment. Recent studies have also
shown that pro- and anti-angiogenic PRP compo-
nents are segregated within granules and can be re-
leased selectively27, suggesting that the use of ‘total’
activated PRP to treat all types of tissue injuries may
not be optimal. Therefore, selective release of specif-
ic molecular components within PRP preparations
may improve healing outcomes. 
Other varying factors frequently used in clinical stud-
ies are the various outcome measures of PRP treat-
ment, including VAS (Visual Analog Scale), DASH
(Disabilities of the Arm, Shoulder, and Hand), and
VISA-A (Victorian Institute of Sport Assessment-
Achilles) scale scores. While these scoring systems
are necessary in patient PRP studies, they are based
on patients’ own assessment of pain intensity and ten-
don function as well and thus unavoidably subjective
and highly variable. To compensate such large vari-
ability, studies should include a large population of pa-
tients to assess the efficacy of PRP treatment. How-
ever, the sample sizes in a number of patient studies
have been relatively small6,10,11. Indeed, patient stud-
ies with greater statistical power as well as adequate
outcome measures have been called for28, 29.
As demonstrated by many previous studies and our
own basic science research, PRP is likely a promis-
ing treatment to enhance the healing of injured ten-
dons, but the factors mentioned above should be
considered in current clinical practices and in the de-
sign of experimental research. This field would ad-
vance immensely with the optimization of PRP factors
through additional basic science studies performed
under well-controlled conditions30. We have linked at
least one PRP component (HGF) to reduced inflam-
mation and pain during tendon healing15. Additional
studies that target various PRP components in vivo
are needed to better understand their functions and
enable the delivery of personalized PRP to patients.
To ensure the efficacy of PRP treatment, guidelines
for such treatment should be formulated based on the
findings of basic science studies. It is anticipated that
by optimizing PRP-associated factors and patient-re-
lated factors, we can effectively treat injured tendons
in clinics. 
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